Current Neurology and Neuroscience Reports

, Volume 12, Issue 3, pp 286–293 | Cite as

Temozolomide Dosing Regimens for Glioma Patients

  • Herwig M. StrikEmail author
  • Christine Marosi
  • Bernd Kaina
  • Bart Neyns
Neuro-Oncology (LE Abrey, Section Editor)


Even in modern times of high-precision brain surgery and irradiation, malignant gliomas belong to the deadliest types of cancer. Due to a marked primary and presumably also acquired resistance, the beneficial effects of cytotoxic chemotherapy are limited. Only one randomized clinical trial demonstrated a significant impact on overall survival with temozolomide. Ever since, there have been attempts to improve the efficacy of alkylating chemotherapy by modulating the distribution of dose in time aiming at a better treatment success. Apart from higher cumulative doses per cycle, better efficacy by depletion of the anti-alkylating O6-methylguanine-DNA methyltransferase (MGMT) protein has been a major goal of these regimens. After promising results of single-arm pilot studies, however, randomized studies have been disappointing so far. In this overview, the different strategies of dose-dense temozolomide regimen are highlighted and results of clinical trials put into perspective.


Chemotherapy Glioblastoma Temozolomide Nitrosourea MGMT 



Conflicts of interest: H.M. Strik: has been a consultant for Micromet; has received grant support from Medac GmbH, Novartis, Mundipharma; has received payment for lectures including service on speakers bureaus from Mundipharma and Essex/Merck; has received payment for development of educational presentations from Mundipharma; has received travel/accommodations/meeting expenses unrelated to activities listed from Medac, Mundipharma, and Essex/Merck; C. Marosi: none; B. Kaina: none; B. Neyns: none.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Walker MD, Green SB, Byar DP, Alexander Jr E, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial: J Clin Oncol. 2001;19:509–18.Google Scholar
  4. 4.
    Weller M, Muller B, Koch R, Bamberg M, Krauseneck P. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol. 2003;21:3276–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRefGoogle Scholar
  6. 6.
    •• Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66. This follow-up analysis provides an update of data on the only landmark study that clearly demonstrated superiority of combined radiochemotherapy over radiotherapy alone. The rate of long-term survivors over 5 years underlines the superiority of this approach over concepts without chemotherapy.PubMedCrossRefGoogle Scholar
  7. 7.
    Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, Sommer C, et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer. 2010;127:2106–18.PubMedCrossRefGoogle Scholar
  8. 8.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.PubMedCrossRefGoogle Scholar
  9. 9.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, et al. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol. 2010;15:352–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Thon N, Eigenbrod S, Grasbon-Frodl EM, Lutz J, Kreth S, Popperl G, et al. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. J Neurol Neurosurg Psychiatry. 2011;82:441–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Gallego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29:3050–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Canc. 2011.Google Scholar
  14. 14.
    Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 2007;6:1079–99.CrossRefGoogle Scholar
  15. 15.
    Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007;26:186–97.PubMedCrossRefGoogle Scholar
  16. 16.
    Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296–307.PubMedCrossRefGoogle Scholar
  17. 17.
    Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Kaina B, Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther. 2002;40:354–67.PubMedGoogle Scholar
  19. 19.
    Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle. 2010;9:168–78.PubMedCrossRefGoogle Scholar
  20. 20.
    Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357–61.PubMedCrossRefGoogle Scholar
  21. 21.
    Soffietti R, Ruda R, Trevisan E, Laguzzi E, Guarneri C, Bomprezzi M, Caroli M. Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: a phase II AINO study [abstract 2019]. J Clin.Oncol. 26. 2008.Google Scholar
  22. 22.
    Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2006;95:1155–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Strik HM, Buhk JH, Wrede A, Hoffmann A, Bock H, Chistmann M, et al. Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Mol Med Rep. 2008;1:863–9.Google Scholar
  24. 24.
    Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, et al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Canc Investig. 2008;26:269–77.CrossRefGoogle Scholar
  25. 25.
    Berrocal A, Perez SP, Gil M, Balana C, Garcia LJ, Yaya R, et al. Extended-schedule dose-dense temozolomide in refractory gliomas. J Neurooncol. 2010;96:417–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, et al. Temozolomide 3 weeks on and 1 week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol. 2008;89:179–85.PubMedCrossRefGoogle Scholar
  27. 27.
    Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol. 2007;82:281–8.PubMedCrossRefGoogle Scholar
  28. 28.
    •• Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28:4601–8. This large, prospective, randomized study compared PCV with two different temozolomide dosing regimen. Surprisingly, no difference of efficacy was found. PubMedCrossRefGoogle Scholar
  29. 29.
    •• Gilbert MR, Wang KD, Aldape R, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal A, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta M. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide(TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma. J Clin Oncol. 29: 2011 (suppl; abstr 2006). This well-conducted, large landmark study provides a prospective, randomized comparison of conventionally dosed and dose-dense temozolomide in newly diagnosed glioblastoma. However, detailed data on adherence to treatment are pending. Google Scholar
  30. 30.
    Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol. 2005;131:31–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer. 2008;113(8):2152–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol. 2002;4:39–43.PubMedGoogle Scholar
  33. 33.
    Strik HM, Bock H, Marosi C. Use of Tegwondo, a near-continuous temozolomide regimen, in high- and low-grade gliomas. J.Clin.Oncol. 29[(suppl; abstr 2084)]. 2011.Google Scholar
  34. 34.
    Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, et al. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010;12:1167–72.PubMedCrossRefGoogle Scholar
  35. 35.
    Preuss I, Thust R, Kaina B. Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer. 1996;65:506–12.PubMedCrossRefGoogle Scholar
  36. 36.
    Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998;16:3310–5.PubMedGoogle Scholar
  37. 37.
    Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol. 2006;24:4412–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Koller CA, Gorski CC, Benjamin RS, Legha SS, Papadopoulos NE, Plager C. A phase I trial of weekly lomustine in patients with advanced cancer. Cancer. 1994;73:236–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Strik HM, Bock H, Kallenberg K. Near-continuous temozolomide and low-dose weekly CCNU: a novel chemotherapy regimen with activity in malignant gliomas resistant to dose-dense temozolomide alone. J Clin Oncol. 28, 2010 (suppl; abstr e12544).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Herwig M. Strik
    • 1
    Email author
  • Christine Marosi
    • 2
  • Bernd Kaina
    • 3
  • Bart Neyns
    • 4
  1. 1.Department of Neurology, Medical SchoolUniversity of MarburgMarburgGermany
  2. 2.Department of Medical OncologyUniversity of ViennaViennaAustria
  3. 3.Institute of ToxicologyUniversity Medical CenterMainzGermany
  4. 4.Medische OncologieBrusselBelgium

Personalised recommendations